Beijing Tiantan Biological Products' (SHA:600161) unit, Chengdu Rongsheng Pharmaceutical, plans to officially start the phase III clinical trials for its human coagulation factor IX, according to a Shanghai Stock Exchange disclosure on Tuesday.

The drug will be tested as a treatment of bleeding in patients with factor IX deficiency or hemophilia B, the disclosure said.

The pharmaceutical company obtained the approval for the trials after completing the Chinese drug administration's clinical ethics review and clinical pre-enrollment preparations.